clinical trial · NCT06134232
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon·phase2·recruiting·n = 400
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Sipuleucel-T Injection
brief summary
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
started
Oct 2, 2023
primary completion
Dec 31, 2031
completion
Jun 30, 2032
last updated
Aug 27, 2025
detailed description
Those enrolled in the Booster Study will have had their course of treatment with PROVENGE® immunotherapy and then randomized to the Booster Study to be treated with a single booster dose of sipuleucel-T.
official title
An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol